For years, Good Distribution Practice (GDP) guidelines have helped protect temperature-sensitive pharmaceuticals through rigorous temperature mapping, validated storage environments, and documented response procedures. But a growing challenge is emerging that these frameworks were never designed to address: increasingly unpredictable weather patterns.

In this article, Kasper Ernest, Director General of GIRP, explains why the greatest threat is no longer sustained heat or prolonged cold, but rapid and extreme fluctuations between the two. As seasonal norms disappear, pharmaceutical distributors are being forced to rethink how they safeguard product integrity in an era of climate volatility.